Summary
Materials and methods

Synthesis of mono-Mannich bases (Igl-Ig4) and corresponding azines (D1-D4)
The syntheses of the compounds have been described in our previous study [14] . Corresponding azine derivatives of mono-Mannich bases
Introduction
Epilepsy treatment is still one of the major problems in medicine. Although there are a number of antiepileptic drugs available in the market, because of some uncontrolled seizures and side effects of currently used drugs, development of new compounds having anticonvulsant activity is still necessary [1] . Most of the drugs used in the treatment of epilepsies today contain a ureid structure such as barbiturates, glutarimides, oxazolidinediones and succinimides [2] [3] [4] . Mannich bases are the compounds which are generally formed by the reaction between a compound containing a reactive hydrogen atom, formaldehyde (or other aldehydes) and amine (mostly secondary amine. primary amine or ammonia) [16] . These compounds have several biological activities such as antimicrobial [5-91, cytotoxic [10-15] , anticancer [16] , analgesic and anti-inflammatory [17] [18] [19] , and anticonvulsant activity [20] [21] [22] [23] . Having the anticonvulsant activity of Mannich bases of conjugated arylidene ketones [22] , Mannich bases of 1-aryl-l-ethanones [24] , 3,3'-methylimino bis(l-aryl-l-propanone)hydrochlorides, which are bisMannich bases derived from acetophenone and 1-methyl-3-aroyl-4-phenyl-4-piperidinol hydrochlorides [21] led us to design and synthesize some mono-Mannich bases, 3-amino-l-aryl-l-propanone hydrochlorides (Ig1-Ig4), to investigate their anticonvulsant activities. Corresponding azine derivatives (D1-D4) of mono-Mannich bases (Igl-Ig4, respectively) were also synthesized to follow the alterations in biological activity by conversion of mono-Mannich bases to corresponding azine derivatives ( 
Anticonvulsant activity
The compounds were tested for their anticonvulsant activity against MES (maximal electroshock) and scMet (subcutaneous metrazole [pentetrazol]) induced seizures. The MES test is a predictor of compounds that are active against grand mal seizures, while the scMet test is used to detect compounds useful in treating petit mal seizures [25] .
Stimulator (Grass S88, Grass Instrument, West Warwick, RI, USA) constant current unit (Grass SCUIA), and corneal electrode were used for the evaluation of anticonvulsant activity. All synthesized compounds were administered intraperitoneally (i. p.) as 30 % aqueous polyethylene (PEG) 400 suspensions. Twelve Swiss albino male mice (20 ± 2g) were used for each compound. The animals used in this experiment were subjected to a previous rotorod toxicity test to confirm that they did not have any congenital neurological defects. Following this test the healthy animals were included into anticonvulsant activity tests. Animals were supplied from the Hacettepe University Animal Farm and in vivo tests were realized according to the NINCDS-ADO (Antiepileptic Drug Development) programme [25) . Control animals received 30 % aqueous PEG 400. The compounds were tested for their anticonvulsant activity against MES and scMet induced seizures. The rotorod toxicity test was performed for neurological toxicity according to the phase I tests of the ADD programme [25] which was also used for evaluation in our previous study [21] . Pentetrazol was administered subcutaneously (s. c.) from the back of the neck. The rotorod toxicity test was performed on a 1 inch diameter knurled wooden rod, rotating at 6 rpm (the rotorod used in Screening I test had been made at the Hacettepe University Technical Department).
MES test
Maximal electroshock seizures were elicited with a 60 cycle alternating current of 50 mA intensity (5-7 times that required to elicit minimal electroshock seizures) delivered for 0.2 s via cornea] electrodes. A drop of 0.9 % saline was instilled into Ihe eye prior to application of the electrodes in order to prevent the death of the animal. Abolition of the hind limb tonic extension component of the seizure was defined as protection.
scMet test
85 mg/kg of pentetrazol (producing seizures in more than 95 % of mice) was administered s. c. as a 0.5 % solution in the posterior midline. The animal was observed for 30 min. Failure to observe even a threshold seizure (a single episode of clinical spasms of at least 5 s duration) was defined as protection.
Neurotoxicity
The rotorod test was used to evaluate neurotoxicity. The animal was placed on a 1 inch diameter knurled wooden rod rotating at 6 rpm. Normal mice remain on a rod rotating at this speed indefinitely. Neurologic toxicity was defined as the failure of the animal to remain on the rod for 1 min.
Results
The anticonvulsant activities of the compounds were initially evaluated against MES and scMet induced seizures using Swiss albino male mice (20 ± 2 g). The results are presented in Table 2 . According to the activity studies, it was determined that the synthesized compounds did not show any protection in the scMet test. Neurotoxicity is not observed in any of the synthesized compounds which were administered in mice in the dose range of 30-300 mg/kg within 0.5 and 4 h. Measurements could not be realized when compounds Ig2, Dl and D2 were administered at 100 mg/kg and compound Igl at 300 mg/kg, since the mice died within 10 min. Compounds Igl, Ig2, Ig3 and Dl were found to be protective against MES seizures at 30 mg/kg dose and above, whereas compound D3 was found to be protective at 100 mg/kg and above. Of all the compounds, Ig4 and D4 were found to be active at 300 mg/kg dose level. 
Discussion
Azine derivatives D2-D4 are new. Conversion of monoMannich bases to their corresponding azine derivatives generally decreased the anticonvulsant activity. Liposolubility of the compounds is important to cross the blood-brain barrier to exert anticonvulsant activity. It is known that mono-Mannich bases undergo deamination to give α,β-unsaturated ketones.
Mono-Mannich bases produce compound 1 after deamination (Fig. 1) , which has a lipophilic aromatic ring and an unsaturated ketone group. It is expected that azine derivatives undergo deamination as shown in Fig.  2. Compound 3 (Fig. 2) , which is expected to be formed from azine derivatives, can produce 2 mol of compound 1 and 1 mol hydrazine by undergoing further biotransformation. Thus, twice the increased biological activity compared with the mono derivatives can be expected with azine derivatives.
As shown in Fig. 3 , azine derivatives are expected to undergo deamination to give 1 mol hydrazine and 2 mol of mono-Mannich base per mol, which will also undergo deamination to give compound 1 eventually. In other words, azines should be able to produce the same lipophilic compound two times more than monoMannich bases and therefore should show higher anticonvulsant activity. However, this was not the case. 1 lie decrease in anticonvulsant activity may be explained by a suggested mechanism as shown in Fig. 4 . Compound 8 may be produced as a result of in vivo biotransformation of azines. It has an aromatic ring but not an unsaturated center between carbon atoms (C=C). Compound 8 has two nitrogen atoms in the cyclic part of the compound. This probably results in an increase in polarity and less liposolubility of compound 8 in comparison to compound 1, and therefore may be responsible for the decreased anticonvulsant activity in azines.
Compound 8 is more stable compared with its precursors, compounds 7 and 1, according to the theoretically calculated thermodynamic enthalpy results (obtained by ChemOffice 2002 software, CambridgeSoft, Cambridge, MA, USA) [14] . These theoretically calculated enthalpy results seem to support the formation of compound 8 rather than compounds 1 and 3, where the anticonvulsant activity was either not affected or decreased in azine derivatives compared to mono-Mannich bases they are derived from contrary to the expectation.
Chemical structures of Mannich bases previously synthesized and studied for anticonvulsant activity are l-aryl-5-dimethylamino-l-penten-3-one hydrochlorides [22] , Mannich bases of f-aryl-1-ethanones [24] , 3,3'-methylimino-bis(f-aryl-l-propanone) hydrochlorides [21] , and l-methyl-3-aroyl-4-aryl-4-piperidinol hydrochlorides [21] . Aryl and carbonyl groups are present in all these compounds. The carhonyl group may be located next to (lie aryl group [21] or somewhere else in the chemical structure [22] . l-Aryl-5-di- methylamino-l-penten-3-one hydrochlorides [22] , Mannich bases of 1-aryl-l-ethanones [24] and 3,3'-methylimino bis(1-aryl-1-propanone) hydrochlorides [21] have a hydrogen atom at β position to amine when their structures was taken into account, and they may undergo deamination producing α,β-unsaturated ketones. It is possible that l-methyl-3-aroyl-4-aryl-4-piperidinol hydrochlorides [21] exert their anticonvulsant activity via producing α,β-unsaturated ketones. The compound Cl having this chemical sturucture, in which the aryl group is phenyl, gave the compound, 3-(2-hydroxyethylthio)-l-phenyl-l-propanone, in the stability study carried out in phosphate buffer using 2-mercaptoethanol at 37 °C [8] . This suggests that Cl produces the adduct, 3-(2-hydroxyethylthio)-1-phenyl-1-propanone, by producing α,β-unsaturated ketone, which reacts with the thiol group of 2-mercaptoethanol.
In this study, anticonvulsant activity was higher in mono-Mannich bases, 3-amino-l-aryl-1-propanone hydrochlorides (Igl-Ig4), while it was lower or absent in the corresponding azine derivatives, N,N'-bis(3-amino-l-aryl-propylidene)hydrazine dihydrochlorides (D1-D4). These findings suggest that the presence of a free aroyl group and the production of an α,β-unsaturated ketone group in vivo seem to play a major role in the anticonvulsant activity of the compounds syntesized.
Conclusion
Conversion of mono-Mannich bases to their corresponding azine derivatives generally decreased the anticonvulsant activity. The presence of a free aroyl group, and also the production of the α,β-unsaturated ketone group in vivo seem to play an important role in the anticonvulsant activity of the compounds syntesized. Ig3, Ig4 and D4 are regarded as candidates to develop new compounds with anticonvulsant activity, especially for grand mal epilepsy, since they were effective in MES screening and did not show any neurotoxicity.
